Catherine Elliott

Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial

Paul E. Goss, James N. Ingle, Kathleen I. Pritchard et al. · Journal of Clinical Oncology · 2013 · 260 citations

Medicine, Oncology, Pharmacology +17

Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial

Paul E. Goss, Dawn L. Hershman, Angela M. Cheung et al. · The Lancet Oncology · 2014 · 53 citations

Medicine, Oncology, Pharmacology +17

Mammographic Breast Density Response to Aromatase Inhibition

Celine M. Vachon, Vera J. Suman, Kathleen R. Brandt et al. · Clinical Cancer Research · 2013 · 33 citations · Full text

Medicine, Endocrinology, Oncology +15

Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor–Treated Patients: CCTG MA.27

Kathrin Strasser‐Weippl, Michaela J. Higgins, Judith‐Anne W. Chapman et al. · JNCI Journal of the National Cancer Institute · 2018 · 24 citations · Full text

Medicine, Oncology, Pharmacology +13

Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor–positive breast cancer: NCIC CTG MA.27

Allan Lipton, Judith‐Anne W. Chapman, Kim Leitzel et al. · Cancer · 2017 · 14 citations · Full text

Medicine, Oncology, Bone Metabolism +16